About: Molecular mechanisms underlying levodopa-induced dyskinesia.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular mechanisms underlying levodopa-induced dyskinesia. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on January 2008

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2008 (ast) наукова стаття, опублікована в січні 2008 (uk) scientific article published on January 2008 (en) مقالة علمية نشرت في يناير 2008 (ar)
publication date	wds:Q37264455-70F2D56D-B7D6-4468-BFA7-36D109944E8B
publication date	2008-01-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37264455-E59B1888-4BC2-4D3B-AB63-387EB8EDEF11
language of work or name	English
cites work	wds:Q37264455-06A5094C-ED14-4E49-973F-76E5435E4443 wds:Q37264455-BA31FCFB-DF96-4130-B4EB-C8A73929343B wds:Q37264455-D86298BC-F4E1-431D-AB2D-E92EA4746297
cites work	Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease Industry forum: Progress in pursuit of therapeutic A2A antagonists: The adenosine A2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys
author name string	wds:Q37264455-56F95A70-5A95-4E1D-AAB7-5C7732EA80C5 wds:Q37264455-E902B0FE-5EC8-434D-B33B-C0EDA869EFE1
author name string	Paolo Calabresi Massimiliano Di Filippo
rdfs:label	Molecular mechanisms underlying levodopa-induced dyskinesia. (en) Molecular mechanisms underlying levodopa-induced dyskinesia. (nl) Molecular mechanisms underlying levodopa-induced dyskinesia. (ast)
skos:prefLabel	Molecular mechanisms underlying levodopa-induced dyskinesia. (en) Molecular mechanisms underlying levodopa-induced dyskinesia. (nl) Molecular mechanisms underlying levodopa-induced dyskinesia. (ast)
name	Molecular mechanisms underlying levodopa-induced dyskinesia. (en) Molecular mechanisms underlying levodopa-induced dyskinesia. (nl) Molecular mechanisms underlying levodopa-induced dyskinesia. (ast)
author	wds:Q37264455-453CF5A7-F7AB-4E76-AEDB-BE0E23ACDCDE wds:Q37264455-53ECEC3D-B599-4CDD-BF80-5B04410A24D2
author	Barbara Picconi Veronica Ghiglieri
title	wds:Q37264455-73072CD5-54CD-41B2-BB1C-756E26BF4005
title	Molecular mechanisms underlying levodopa-induced dyskinesia (en)
page(s)	wds:Q37264455-75D73423-518E-4DCE-A86D-9A47AF352E3E
page(s)	S570-9
instance of	wds:Q37264455-1D4DF7EA-A68C-46CF-96EB-D36C75D6CB08 wds:Q37264455-c4d3c5b3-62ff-4b72-bdbd-5f1db8cd9709
instance of	review article scholarly article
main subject	wds:Q37264455-7C43CADA-CFE4-46BE-9235-A46B1F019397 wds:Q37264455-F67A8B3A-4960-4E0A-8F9A-7ED546A986E8
main subject	wd:Q300989 dyskinesia
PubMed ID	wds:Q37264455-6800F8E1-11B2-405B-AB22-0579DD597628
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18781674
PubMed ID	18781674
published in	wds:Q37264455-BA08E190-03DC-46CC-B715-41E2CD33CE1B
published in	Movement Disorders
volume	wds:Q37264455-5970DC24-9F25-4309-A8DC-F6910F03FFC8
volume	23 Suppl 3
DOI	wds:Q37264455-5299F2D0-8FC1-427D-AE54-641F77BA27CD
DOI	http://dx.doi.org/10.1002/MDS.22019
DOI	10.1002/MDS.22019
ResearchGate publication ID	wds:Q37264455-3273A1B1-B991-480C-863B-F2E4AA329EE2
ResearchGate publication ID	227772093
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37264455
is cites work of	Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Major nutritional issues in the management of Parkinson's disease wd:Q64760953 wd:Q64761368 Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. Chronic levodopa administration followed by a washout period increased number and induced phenotypic changes in striatal dopaminergic cells in MPTP-monkeys Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia Convergent evidence for abnormal striatal synaptic plasticity in dystonia Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia Multiple roles for nicotine in Parkinson's disease The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease Therapies for dopaminergic-induced dyskinesias in Parkinson disease Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease Dysregulation of striatal projection neurons in Parkinson's disease Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. Motor complications, levodopa metabolism and progression of Parkinson's disease Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software